- Home
- CNFR vs GOVX Comparison
CNFR vs GOVX Comparison
Compare CNFR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- GOVX
- Stock Information
- Founded
- CNFR 2009
- GOVX 2001
- Country
- CNFR United States
- GOVX United States
- Employees
- CNFR N/A
- GOVX N/A
- Industry
- CNFR Property-Casualty Insurers
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- GOVX Health Care
- Exchange
- CNFR Nasdaq
- GOVX Nasdaq
- Market Cap
- CNFR 9.4M
- GOVX 7.6M
- IPO Year
- CNFR 2015
- GOVX N/A
- Fundamental
- Price
- CNFR $0.81
- GOVX $0.69
- Analyst Decision
- CNFR
- GOVX Strong Buy
- Analyst Count
- CNFR 0
- GOVX 5
- Target Price
- CNFR N/A
- GOVX $12.40
- AVG Volume (30 Days)
- CNFR 4.5K
- GOVX 3.3M
- Earning Date
- CNFR 08-12-2025
- GOVX 08-05-2025
- Dividend Yield
- CNFR N/A
- GOVX N/A
- EPS Growth
- CNFR N/A
- GOVX N/A
- EPS
- CNFR 1.96
- GOVX N/A
- Revenue
- CNFR $64,021,000.00
- GOVX $5,591,576.00
- Revenue This Year
- CNFR $25.91
- GOVX N/A
- Revenue Next Year
- CNFR N/A
- GOVX N/A
- P/E Ratio
- CNFR $0.41
- GOVX N/A
- Revenue Growth
- CNFR N/A
- GOVX N/A
- 52 Week Low
- CNFR $0.42
- GOVX $0.43
- 52 Week High
- CNFR $1.91
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- CNFR 44.32
- GOVX 42.50
- Support Level
- CNFR $0.73
- GOVX $0.60
- Resistance Level
- CNFR $0.81
- GOVX $0.77
- Average True Range (ATR)
- CNFR 0.03
- GOVX 0.09
- MACD
- CNFR -0.00
- GOVX -0.01
- Stochastic Oscillator
- CNFR 21.66
- GOVX 47.27
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.